Cargando…
Structure-Based Inhibitor Discovery of Class I Histone Deacetylases (HDACs)
Class I histone deacetylases (HDACs) are promising targets for epigenetic therapies for a range of diseases such as cancers, inflammations, infections and neurological diseases. Although six HDAC inhibitors are now licensed for clinical treatments, they are all pan-inhibitors with little or no HDAC...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7700698/ https://www.ncbi.nlm.nih.gov/pubmed/33266366 http://dx.doi.org/10.3390/ijms21228828 |